Analysts See $-0.42 EPS for Viveve Medical, Inc. (VIVE)

May 9, 2018 - By sdfsdfsdf

Analysts expect Viveve Medical, Inc. (NASDAQ:VIVE) to report $-0.42 EPS on May, 10.They anticipate $0.15 EPS change or 26.32 % from last quarter’s $-0.57 EPS. After having $-0.53 EPS previously, Viveve Medical, Inc.’s analysts see -20.75 % EPS growth. The stock decreased 4.75% or $0.15 during the last trading session, reaching $3.01. About 180,928 shares traded. Viveve Medical, Inc. (NASDAQ:VIVE) has declined 30.87% since May 9, 2017 and is downtrending. It has underperformed by 42.42% the S&P500.

Viveve Medical, Inc. designs, develops, makes, and markets medical devices for the non-invasive treatment of vaginal laxity. The company has market cap of $94.01 million. The firm offers Geneveve, a non-invasive solution that includes the Viveve System, a radio frequency generator; a reusable hand piece and single-use treatment tip; and other consumable accessories. It currently has negative earnings. It markets its products through sales employees and distributors in Asia, Europe, the Middle East, Latin America, the United States, Canada, and internationally.

More recent Viveve Medical, Inc. (NASDAQ:VIVE) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on April 17, 2018. Also Streetinsider.com published the news titled: “Stifel Starts Viveve Medical (VIVE) at Buy” on April 16, 2018. Globenewswire.com‘s news article titled: “Viveve to Announce First Quarter 2018 Financial Results” with publication date: May 03, 2018 was also an interesting one.

Viveve Medical, Inc. (NASDAQ:VIVE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.